MedPath

PHYTOHEALTH CORPORATION

🇹🇼Taiwan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

18

Active:0
Completed:12

Trial Phases

4 Phases

Early Phase 1:1
Phase 1:3
Phase 2:12
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials

Phase 2
12 (70.6%)
Phase 1
3 (17.6%)
Early Phase 1
1 (5.9%)
Phase 4
1 (5.9%)

PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients

Phase 2
Recruiting
Conditions
Cancer-related Fatigue
Interventions
Drug: PG2 Lyo. Injection 500mg
Drug: Placebo 0.9% normal saline
First Posted Date
2022-06-30
Last Posted Date
2025-06-05
Lead Sponsor
PhytoHealth Corporation
Target Recruit Count
36
Registration Number
NCT05440227
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer

Phase 2
Completed
Conditions
Cancer-related Fatigue
Survival
Tumor, Esophageal
Interventions
Drug: Astragalus Polysaccharides 500 mg
First Posted Date
2018-08-02
Last Posted Date
2025-06-04
Lead Sponsor
PhytoHealth Corporation
Target Recruit Count
48
Registration Number
NCT03611712
Locations
🇨🇳

Mackay Memorial Hospital, Taipei, Taiwan

🇨🇳

Tri-Service General Hospital, Taipei, Taiwan

🇨🇳

Far Eastern Memorial Hospital, Taipei, Taiwan

and more 1 locations

PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

Phase 2
Completed
Conditions
Neutropenia, Malignant
Cancer-related Fatigue
Interventions
Drug: Placebo
Drug: Astragalus polysaccharides 500 mg
Procedure: EC Chemotherapy
First Posted Date
2017-10-19
Last Posted Date
2025-06-04
Lead Sponsor
PhytoHealth Corporation
Target Recruit Count
67
Registration Number
NCT03314805
Locations
🇨🇳

Chang Gung Memorial Hospital, Lovers Lake branch, Keelung, Taiwan

🇨🇳

E-Da Cancer Hospital, Kaohsiung City, Taiwan

🇨🇳

Chang Gung Memorial Hospital, Kaohsiung Branch, Kaohsiung City, Taiwan

and more 2 locations

Study of PHN131 in Patients After Surgery

Phase 2
Completed
Conditions
Analgesia Disorder
Interventions
Drug: Placebo soft capsules
Drug: PHN131 soft capsule with Nalbuphine HCl 60 mg/cap
Drug: Dicofenac
First Posted Date
2014-07-17
Last Posted Date
2025-06-05
Lead Sponsor
PhytoHealth Corporation
Target Recruit Count
106
Registration Number
NCT02193620
Locations
🇨🇳

General Clinical Research Center, Tri-service General Hospital, Taipei city, Taiwan

Study of PHN131 in Healthy Volunteers

Terminated
Conditions
Analgesia Disorder
First Posted Date
2014-07-16
Last Posted Date
2025-06-06
Lead Sponsor
PhytoHealth Corporation
Target Recruit Count
16
Registration Number
NCT02192151
Locations
🇨🇳

General Clinical Research Center, Tri-service General Hospital, Taipei, Taiwan

  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

PG2® Plus Chemoradiotherapy Improves Survival in Esophageal Cancer Patients

A clinical study by PhytoHealth Corporation shows that Astragalus Polysaccharides (PG2®) combined with chemoradiotherapy (CCRT) significantly improves survival in advanced esophageal cancer patients.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.